课题基金 / 基金详情

Use p105(sr) to study p50 homodimer in skin tumor/cancer

Use p105(sr) to study p50 homodimer in skin tumor/cancer
使用 p105(sr) 研究皮肤肿瘤/癌症中的 p50 同二聚体
批准号:
7024977
负责人:
LI LIN
金额:
$20.94万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-07-01 至 2010-02-28
关键词:

项目摘要

项目成果

LI LIN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): NF-kappaB plays a significant role in tumori- and carcinogenesis. Constitutively active NF-kappaB has been detected in several types of tumors and cancers. However, unlike other types of cancers where NF-kappaB heterodimer p50/RelA activity is elevated, chemical-induced skin papillomas and squamous cell carcinomas (SCC), exhibit significantly elevated p50 homodimer activity. The cause of this elevation in skin tumors and cancers, what are the genes regulated by p50 homodimer, and how these genes contribute to tumorigenesis and malignancy are unknown. SCCs are also known for their resistance to cancer therapies. Introduction of kappa-B-alpha-based NF-kappaB super represser (sr) into cancer cells has led to successful dissection of the NF-kappaB target genes via DNA microarray analysis. Repression of NF-kappaB activities by this method also facilitates tumor necrosis factor alpha (TNFalpha)-, or chemotherapy reagents-induced apoptosis in cancer cells. Since p50 homodimer activities are not regulated by prototypic kappaBs, such approach cannot be applied to skin tumors and cancers. We have developed an NF-kappaB super represser based on NF-kappaB inhibitor p105, and demonstrated that p105(sr) broadly and effectively inhibits all NF-kappaB species. Overexpression of p105(sr) generates p105(sr)/p50 heterodimers and therefore, prevents formation of p50 homodimers. Formation of p105(sr)/Rel protein complexes should broadly inhibit NF-kappaB activities. Our long-term goal is to understand the role of NF-kappaB in tumorigenesis. We hypothesize that carcinogen TPA treatment of skin leads to enhanced turnover of p50 precursor p105, releasing p50 to form homodimers. The p50 homodimer, in synergy with constitutively activated Ha-ras in skin tumors, plays a role in tumorigenesis. Introduction of p105(sr) into skin tumor cells will lead to systematic dissection of NF-kappaB-regulated genes including those controlled by p50 homodimers. Such approach will also aid to facilitate apoptosis of the tumor cells mediated by TNFalpha, and chemotherapy reagents. We will study the mechanism of how p50 homodimer activity is elevated in skin tumor cells. We will also test whether introducing p105(sr) into skin tumor cells facilitates apoptosis, and whether this approach significantly affects physiologic functions of normal keratinocytes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Emergency Department Simulation for Research and Training in Health Care IT
Emergency Department Simulation for Research and Training in Health Care IT
Use p105(sr) to study p50 homodimer in skin tumor/cancer
Use p105(sr) to study p50 homodimer in skin tumor/cancer
  • 批准号:
    6922572
  • 项目类别:
  • 资助金额:
    $5.8万
  • 财政年份:
    2005
  • 负责人:
    LI LIN
  • 依托单位:
国内基金
海外基金
TRIM28介导P105泛素化激活NF-κB通路驱动TMZ诱导胶质瘤细胞衰老的机制及靶向干预研究
  • 批准号:
    2026JJ60088
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    周权炜
  • 依托单位:
IKKβ激酶的底物差异识别机制及其在炎症性肠病中的功能研究
  • 批准号:
    32000628
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2020
  • 负责人:
    张瑜
  • 依托单位:
蛋白激酶MAP3K8激活的生化机制
  • 批准号:
    31071242
  • 项目类别:
    面上项目
  • 资助金额:
    35.0万元
  • 批准年份:
    2010
  • 负责人:
    夏总平
  • 依托单位: